Cutter Capital Management
Latest statistics and disclosures from Cutter Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GILD, BMY, RPRX, A, RARE, and represent 33.19% of Cutter Capital Management's stock portfolio.
- Added to shares of these 10 stocks: BMY (+$30M), A (+$18M), LLY (+$15M), REGN (+$15M), JAZZ (+$13M), SWTX (+$12M), PRGO (+$12M), VRDN (+$12M), AXSM (+$9.5M), AGIO (+$8.3M).
- Started 12 new stock positions in LLY, NTLA, AXSM, IOVA, REGN, VRDN, RNA, A, JAZZ, AGIO. SWTX, BMY.
- Reduced shares in these 10 stocks: , , AMGN (-$20M), , KVUE (-$18M), TEVA (-$15M), CYTK (-$13M), CRSP (-$11M), BCRX (-$8.9M), AVTR (-$8.5M).
- Sold out of its positions in AMGN, AVTR, BMRN, BIIB, CYTK, EOLS, KVUE, MRK, PFE, TEVA. CRSP.
- Cutter Capital Management was a net seller of stock by $-14M.
- Cutter Capital Management has $339M in assets under management (AUM), dropping by 2.26%.
- Central Index Key (CIK): 0001983313
Tip: Access up to 7 years of quarterly data
Positions held by Cutter Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cutter Capital Management
Cutter Capital Management holds 27 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Gilead Sciences (GILD) | 8.9 | $30M | +22% | 359k | 83.84 |
|
| Bristol Myers Squibb (BMY) | 8.8 | $30M | NEW | 574k | 51.74 |
|
| Royalty Pharma Shs Class A (RPRX) | 5.6 | $19M | -3% | 665k | 28.29 |
|
| Agilent Technologies Inc C ommon (A) | 5.3 | $18M | NEW | 121k | 148.48 |
|
| Ultragenyx Pharmaceutical (RARE) | 4.7 | $16M | -21% | 287k | 55.55 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 4.7 | $16M | -5% | 326k | 48.73 |
|
| Insmed Com Par $.01 (INSM) | 4.7 | $16M | -5% | 216k | 73.00 |
|
| Eli Lilly & Co. (LLY) | 4.5 | $15M | NEW | 17k | 885.94 |
|
| Regeneron Pharmaceuticals (REGN) | 4.5 | $15M | NEW | 15k | 1051.24 |
|
| Harmony Biosciences Hldgs In (HRMY) | 4.4 | $15M | +27% | 376k | 40.00 |
|
| Perrigo SHS (PRGO) | 4.3 | $15M | +457% | 558k | 26.23 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.9 | $13M | NEW | 118k | 111.41 |
|
| Springworks Therapeutics (SWTX) | 3.6 | $12M | NEW | 379k | 32.04 |
|
| Miragen Therapeutics (VRDN) | 3.5 | $12M | NEW | 519k | 22.75 |
|
| Sarepta Therapeutics (SRPT) | 3.1 | $11M | -23% | 84k | 124.89 |
|
| Bridgebio Pharma (BBIO) | 3.0 | $10M | +27% | 396k | 25.46 |
|
| Axsome Therapeutics (AXSM) | 2.8 | $9.5M | NEW | 106k | 89.87 |
|
| Agios Pharmaceuticals (AGIO) | 2.4 | $8.3M | NEW | 187k | 44.43 |
|
| Iovance Biotherapeutics (IOVA) | 2.4 | $8.2M | NEW | 876k | 9.39 |
|
| Intellia Therapeutics (NTLA) | 2.4 | $8.0M | NEW | 391k | 20.55 |
|
| Vera Therapeutics Cl A (VERA) | 2.3 | $7.6M | -24% | 173k | 44.20 |
|
| Arcellx Common Stock (ACLX) | 2.2 | $7.5M | -51% | 90k | 83.51 |
|
| Avidity Biosciences Ord (RNA) | 2.2 | $7.4M | NEW | 161k | 45.93 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.8 | $6.1M | -59% | 798k | 7.60 |
|
| Enliven Therapeutics (ELVN) | 1.6 | $5.3M | -6% | 208k | 25.54 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 1.5 | $5.1M | -47% | 385k | 13.12 |
|
| Ionis Pharmaceuticals (IONS) | 1.2 | $3.9M | -39% | 97k | 40.06 |
|
Past Filings by Cutter Capital Management
SEC 13F filings are viewable for Cutter Capital Management going back to 2023
- Cutter Capital Management 2024 Q3 filed Nov. 14, 2024
- Cutter Capital Management 2024 Q2 filed Aug. 14, 2024
- Cutter Capital Management 2024 Q1 amended filed Aug. 6, 2024
- Cutter Capital Management 2024 Q1 filed May 15, 2024
- Cutter Capital Management 2023 Q4 filed Feb. 14, 2024